All In MedTech

FDA Clearance Tracker · P010062-S008

BOSTON ORTHOKERATOLOGY (OPRIFOCON A) SHAPING LENS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 28, 2014 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 28, 2014

Approved

Time to decision

1,377 days

Received Oct 20, 2010. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P010062-S008
Device name
BOSTON ORTHOKERATOLOGY (OPRIFOCON A) SHAPING LENS
Applicant
Bausch & Lomb
Applicant location
Rochester, NY
Received
Oct 20, 2010
Decided
Jul 28, 2014
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P010062

Device type

Device class
Class III
Regulation
21 CFR 886.5916
Specialty
Ophthalmology

Every decision under product code NUU

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A LABELING UPDATE TO THE PACKAGE INSERT AND PATIENT INFORMATION BOOKLET TO INCLUDE THE RESULTS FROM A SECTION 522 POSTMARKET SURVEILLANCE STUDY (PAS).

Source documents

Other decisions for Bausch & Lomb

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.